Llausas-Magana E, Hsueh W, Arroyave C M, Arroyave J L, Torre-Amione G, Gonzalez-Crussi F
Department of Pathology, Children's Memorial Hospital, Chicago, IL 60614.
Immunopharmacology. 1988 Jan-Feb;15(1):31-7. doi: 10.1016/0162-3109(88)90040-9.
We have previously produced an experimental model of ischemic bowel necrosis in the rat by injecting platelet activating factor (PAF) (7 micrograms/kg) into the mesenteric vascular bed. The dose of PAF required to produce necrosis could be reduced to 50% if the animal was pretreated with bacterial endotoxin (lipopolysaccharide) (20 micrograms/rat). The mechanism of this potentiating effect of lipopolysaccharide is unclear, but activation of the complement system may be one of the contributing factors. To investigate the role of the complement system, we injected cobra venom factor (CVF) (1 unit/kg) to activate the complement system before injection of PAF (2 micrograms/kg) into the superior mesenteric artery. CVF and PAF were also injected separately at the same dosage to other groups of rats. CVF activated the complement system, but by itself did not produce gross necrosis of the bowel. PAF alone caused 3 out of 9 rats treated to develop bowel necrosis. In contrast, combination of the two produced bowel necrosis in all 6 rats thus treated. CVF did not enhance the effects of PAF on hemoconcentration and leukopenia, but aggravated the hypotension caused by PAF. PAF, on the other hand, also enhanced activation of the complement system by CVF. To investigate the specificity of PAF on complement activation, lyso-PAF was used in combination with CVF. It was found that lyso-PAF did not have a significant potentiating effect on CVF-induced complement activation and, by itself, it had no effect on complement activation, blood pressure, white blood cell count or hematocrit. Lyso-PAF, with or without CVF, also failed to produce bowel necrosis.(ABSTRACT TRUNCATED AT 250 WORDS)
我们之前通过向大鼠肠系膜血管床注射血小板活化因子(PAF)(7微克/千克)建立了缺血性肠坏死的实验模型。如果动物预先用细菌内毒素(脂多糖)(20微克/只大鼠)处理,产生坏死所需的PAF剂量可降低至50%。脂多糖这种增强作用的机制尚不清楚,但补体系统的激活可能是其中一个促成因素。为了研究补体系统的作用,我们在向上肠系膜动脉注射PAF(2微克/千克)之前,注射眼镜蛇毒因子(CVF)(1单位/千克)以激活补体系统。CVF和PAF也以相同剂量分别注射到其他组大鼠体内。CVF激活了补体系统,但自身并未导致肠道出现明显坏死。单独使用PAF时,9只接受治疗的大鼠中有3只出现肠坏死。相比之下,二者联合使用时,接受治疗的6只大鼠均出现肠坏死。CVF并未增强PAF对血液浓缩和白细胞减少的作用,但加重了PAF引起的低血压。另一方面,PAF也增强了CVF对补体系统的激活。为了研究PAF对补体激活的特异性,将溶血PAF与CVF联合使用。发现溶血PAF对CVF诱导的补体激活没有显著的增强作用,并且其本身对补体激活、血压、白细胞计数或血细胞比容均无影响。无论有无CVF,溶血PAF均未导致肠坏死。(摘要截短至250字)